Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 9/2016

01-09-2016 | Original Article

Lung adenocarcinoma may be a more susceptive subtype to a dendritic cell-based cancer vaccine than other subtypes of non-small cell lung cancers: a multicenter retrospective analysis

Authors: Hidenori Takahashi, Shigetaka Shimodaira, Masahiro Ogasawara, Shuichi Ota, Masanori Kobayashi, Hirofumi Abe, Yuji Morita, Kazuhiro Nagai, Shunichi Tsujitani, Masato Okamoto, Yukio Suzuki, Yoichi Nakanishi, Yoshikazu Yonemitsu, for the DC Vaccine Study Group at the Japanese Society of Immunotherapy and Cell Therapy

Published in: Cancer Immunology, Immunotherapy | Issue 9/2016

Login to get access

Abstract

Objective

The J-SICT DC Vaccine Study Group provides dendritic cell (DC) vaccines for compassionate use under unified cell production and patient treatment regimens. We previously reported beneficial effects of DC vaccines on the overall survival of 62 patients with advanced non-small cell lung cancer (NSCLC) in a single-center analysis. Here, we extended analysis to 260 patients with NSCLC who were treated at six centers.

Methods

Of the 337 patients who met the inclusion criteria, we analyzed 260 patients who received ≥5 peptide-pulsed DC vaccinations once every 2 weeks.

Results

The mean survival time (MST) from diagnosis was 33.0 months (95 % confidence interval [CI]: 27.9–39.2), and that from time of first vaccination was 13.8 months (95 % CI 11.4–16.8). An erythema reaction at the injection site that was ≥30 mm in diameter was correlated most strongly with overall survival from the first vaccine (≥30 vs. < 30 mm: MST 20.4 vs. 8.8 months, P < 0.001). We reported a similar finding in our previous analysis of patients with advanced pancreatic cancer. Interestingly, although such findings were common between patients with adenocarcinoma and those with other subtypes, the former group experienced significantly prolonged overall survival and a higher response rate for erythema (56.3 vs. 37.3 %, respectively, P = 0.014).

Conclusions

This is the first multicenter study that suggests a possible clinical benefit of DC vaccines for patients with advanced NSCLC, especially those with adenocarcinoma. These findings suggest a specific potential responder population for DC vaccines and warrant further investigation in well-controlled prospective randomized trials.
Appendix
Available only for authorised users
Literature
1.
2.
Langer CJ, Manola J, Bernardo P, Kugler JW, Bonomi P, Cella D et al (2002) Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94:173–181CrossRefPubMed
3.
Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J et al (2002) Eastern Cooperative Oncology Group Comparison of four chemotherapy regimens for advanced non–small-cell lung cancer. N Engl J Med 346:92–98CrossRefPubMed
4.
Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S et al (2007) Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-Arm Cooperative Study in Japan. Ann Oncol 18:317–323CrossRefPubMed
5.
Paz-Ares LG, Biesma B, Heigener D, von Pawel J, Eisen T, Bennouna J et al (2012) Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol 30:3084–3092CrossRefPubMed
6.
7.
8.
Morse MA, Clay TM, Hobeika AC, Osada T, Khan S, Chui S et al (2005) Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecule. Clin Cancer Res 11:3017–3024CrossRefPubMed
9.
Chang GC, Lan HC, Juang SH, Wu YC, Lee HC, Hung YM et al (2005) A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma. Cancer 103:763–771CrossRefPubMed
10.
Hirschowitz EA, Foody T, Kryscio R, Dickson L, Sturgill J, Yannelli J (2004) Autologous dendritic cell vaccines for non-small-cell lung cancer. J Clin Oncol 22:2808–2815CrossRefPubMed
11.
Takahashi H, Okamoto M, Shimodaira S, Tsujitani S, Nagaya M, Ishidao T, DC-vaccine study group at the Japan Society of Innovative Cell Therapy (J-SICT) et al (2013) Impact of dendritic cell vaccines pulsed with Wilms’ tumour-1 peptide antigen on the survival of patients with advanced non-small cell lung cancers. Eur J Cancer 49:852–859CrossRefPubMed
12.
Kimura Y, Tsukada J, Tomoda T, Takahashi H, Imai K, Shimamura K et al (2012) Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma. Pancreas 41:195–205CrossRefPubMed
13.
Kobayashi M, Sakabe T, Abe H, Tanii M, Takahashi H, Chiba A, DC-vaccine study group at the Japan Society of Innovative Cell Therapy (J-SICT) et al (2013) Dendritic cell-based immunotherapy targeting synthesized peptides for advanced biliary tract cancer. J Gastrointest Surg 17:1609–1617CrossRefPubMed
14.
Kobayashi M, Shimodaira S, Nagai K, Ogasawara M, Takahashi H, Abe H, DC Vaccine Study Group at the Japan Society of Innovative Cell Therapy (J-SICT) et al (2014) Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving chemotherapy: a multicenter analysis. Cancer Immunol Immunother 63:797–806CrossRefPubMed
15.
Kobayashi M, Chiba A, Izawa H, Yanagida E, Okamoto M, Shimodaira S, DC-vaccine study group at the Japan Society of Innovative Cell Therapy (J-SICT) et al (2014) The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer. J Ovarian Res 7:48. doi:10.​1186/​1757-2215-7-48 CrossRefPubMedPubMedCentral
16.
Kobayashi M, Sakabe T, Chiba A, Nakajima A, Okamoto M, Shimodaira S, DC-vaccine study group at the Japan Society of Innovative Cell Therapy (J-SICT) et al (2014) Therapeutic effect of intratumoral injections of dendritic cells for locally recurrent gastric cancer: a case report. World J Surg Oncol 12:390. doi:10.​1186/​1477-7819-12-390 CrossRefPubMedPubMedCentral
17.
Saito S, Yanagisawa R, Yoshikawa K, Higuchi Y, Koya T, Yoshizawa K et al (2015) Safety and tolerability of allogeneic dendritic cell vaccination with induction of Wilms tumor 1-specific T cells in a pediatric donor and pediatric patient with relapsed leukemia: a case report and review of the literature. Cytotherapy 17:330–335CrossRefPubMed
18.
Sakai K, Shimodaira S, Maejima S, Udagawa N, Sano K, Higuchi Y et al (2015) Dendritic cell-based immunotherapy targeting Wilms’ tumor 1 in patients with recurrent malignant glioma. J Neurosurg 123:989–997CrossRefPubMed
19.
Oji Y, Miyoshi S, Maeda H, Hayashi S, Tamaki H, Nakatsuka S et al (2002) Overexpression of the Wilms’ tumor gene WT1 in de novo lung cancers. Int J Cancer 100:297–303CrossRefPubMed
20.
Giatromanolaki A, Koukourakis MI, Sivridis E, O’Byrne K, Cox G, Thorpe PE et al (2000) Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways. Clin Cancer Res 6:1917–1921PubMed
21.
Okamoto M, Furuichi S, Nishioka Y, Oshikawa T, Tano T, Ahmed SU et al (2004) Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation. Cancer Res 64:5461–5470CrossRefPubMed
22.
Okamoto M, Oshikawa T, Tano T, Ohe G, Furuichi S, Nishikawa H et al (2003) Involvement of Toll-like receptor 4 signaling in interferon-gamma production and antitumor effect by streptococcal agent OK-432. J Natl Cancer Inst 95:316–326CrossRefPubMed
23.
Dahlberg SE, Schiller JH, Bonomi PB, Sandler AB, Brahmer JR, Ramalingam SS et al (2013) Body mass index and its association with clinical outcomes for advanced non-small-cell lung cancer patients enrolled on Eastern Cooperative Oncology Group clinical trials. J Thorac Oncol 8:1121–1127CrossRefPubMedPubMedCentral
24.
Leung CC, Lam TH, Yew WW, Chan WM, Law WS, Tam CM (2011) Lower lung cancer mortality in obesity. Int J Epidemiol 40:174–182CrossRefPubMed
25.
Attaran S, McShane J, Whittle I, Poullis M, Shackcloth M (2012) A propensity-matched comparison of survival after lung resection in patients with a high versus low body mass index. Eur J Cardiothorac Surg 42:653–658CrossRefPubMed
26.
Jiang L, Jiang S, Lin Y, Yang H, Zhao Z, Xie Z et al (2015) Combination of body mass index and oxidized low density lipoprotein receptor 1 in prognosis prediction of patients with squamous non-small cell lung cancer. Oncotarget 6:22072–22080CrossRefPubMedPubMedCentral
27.
Mandrekar SJ, Schild SE, Hillman SL, Allen KL, Marks RS, Mailliard JA et al (2006) A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials. Cancer 107:781–792CrossRefPubMed
28.
Luo J, Chen YJ, Narsavage GL, Ducatman A (2012) Predictors of survival in patients with non-small cell lung cancer. Oncol Nurs Forum 39:609–616CrossRefPubMed
29.
Arslan D, Tural D, Koca T, Tastekin D, Kaymak Cerkesli A et al (2015) Prognostic factors in clinical stage T4N2 locally advanced non-small cell lung cancer. J BU ON 20:573–579
30.
Ulas A, Turkoz FP, Silay K, Tokluoglu S, Avci N, Oksuzoglu B et al (2014) A laboratory prognostic index model for patients with advanced non-small cell lung cancer. PLoS ONE 9:e114471CrossRefPubMedPubMedCentral
31.
Yildirim M, Yildiz M, Duman E, Goktas S, Kaya V (2013) Prognostic importance of the nutritional status and systemic inflammatory response in non-small cell lung cancer. J BU ON 18:728–732
32.
33.
Kos FT, Hocazade C, Kos M, Uncu D, Karakas E, Dogan M et al (2015) Assessment of prognostic value of “neutrophil to lymphocyte ratio” and “prognostic nutritional index” as a sytemic inflammatory marker in non-small cell lung cancer. Asian Pac J Cancer Prev 16:3997–4002CrossRefPubMed
34.
Jin Y, Sun Y, Shi X, Zhao J, Shi L, Yu X (2014) Prognostic value of circulating C-reactive protein levels in patients with non-small cell lung cancer: a systematic review with meta-analysis. J Cancer Res Ther 10(Suppl):C160–C166PubMed
35.
Liao C, Yu Z, Guo W, Liu Q, Wu Y, Li Y et al (2014) Prognostic value of circulating inflammatory factors in non-small cell lung cancer: a systematic review and meta-analysis. Cancer Biomark 14:469–481PubMed
36.
de Vries IJ, Bernsen MR, Lesterhuis WJ, Scharenborg NM, Strijk SP, Gerritsen MJ et al (2005) Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol 23:5779–5787CrossRefPubMed
37.
Hersey P, Menzies SW, Halliday GM, Nguyen T, Farrelly ML, DeSilva C et al (2004) Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Cancer Immunol Immunother 53:125–134CrossRefPubMed
38.
Nishida S, Koido S, Takeda Y, Homma S, Komita H, Takehara A et al (2014) Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer. J Immunother 37:105–114CrossRefPubMedPubMedCentral
Metadata
Title
Lung adenocarcinoma may be a more susceptive subtype to a dendritic cell-based cancer vaccine than other subtypes of non-small cell lung cancers: a multicenter retrospective analysis
Authors
Hidenori Takahashi
Shigetaka Shimodaira
Masahiro Ogasawara
Shuichi Ota
Masanori Kobayashi
Hirofumi Abe
Yuji Morita
Kazuhiro Nagai
Shunichi Tsujitani
Masato Okamoto
Yukio Suzuki
Yoichi Nakanishi
Yoshikazu Yonemitsu
for the DC Vaccine Study Group at the Japanese Society of Immunotherapy and Cell Therapy
Publication date
01-09-2016
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 9/2016
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-016-1872-z

Other articles of this Issue 9/2016

Cancer Immunology, Immunotherapy 9/2016 Go to the issue

Original Article

Uptake of synthetic naked RNA by skin-resident dendritic cells via macropinocytosis allows antigen expression and induction of T-cell responses in mice

Original Article

Human NK cells maintain licensing status and are subject to killer immunoglobulin-like receptor (KIR) and KIR-ligand inhibition following ex vivo expansion

Review

Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma

Original Article

Resistance to cytotoxicity and sustained release of interleukin-6 and interleukin-8 in the presence of decreased interferon-γ after differentiation of glioblastoma by human natural killer cells

Original Article

The immunomodulatory, antitumor and antimetastatic responses of melanoma-bearing normal and alcoholic mice to sunitinib and ALT-803: a combinatorial treatment approach

Original Article

B7-H4 expression indicates poor prognosis of oral squamous cell carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits